Nektar narrows loss on 193% revenue boost - 500 Beiträge pro Seite

[summersonflo]

Press Release Source: Nektar Therapeutics


Nektar Therapeutics Announces First Quarter 2007 Results
Wednesday May 9, 4:32 pm ET


SAN CARLOS, Calif.--(BUSINESS WIRE)--Nektar Therapeutics (Nasdaq:NKTR - News) announced today the company's financial results for the first quarter that ended on March 31, 2007:
Revenue totaled $85.0 million compared to $29.0 million in the same period in 2006.
Exubera-related revenue was $59.8 million compared to $1.5 million in the same period in 2006. On January 1, 2007, we began recognizing revenue upon product shipment. First quarter 2007 revenues include $26.0 million resulting from the elimination of the 60-day revenue deferral that was applied to Exubera manufacturing sales to Pfizer in 2006. As a result, the first quarter of 2007 included an additional 60 days of Exubera product sales to Pfizer.
Cash, cash equivalents, and short- and long-term investments of $398.3 million as of March 31, 2007, compared to $467.0 million as of December 31, 2006. In the first quarter of 2007, we repaid $36 million of convertible debt. We also experienced changes in our balance sheet including an increase in receivables and reduction in accounts payable which we do not expect to incur in future quarters in 2007.
Nektar reported a net loss of $25.7 million or $(0.28) per share (which included $6.3 million of stock-based compensation charges) compared to a net loss of $33.5 million or $(0.38) per share in the same period of 2006 (which included $6.9 million of stock-based compensation charges).
"We made significant progress this quarter," said Howard Robin, President and Chief Executive Officer of the company. "In particular, we are excited about the progress we made in PEGylating small molecules. Our two most advanced programs--NKTR-102 -- PEGylated-irinotecan and NKTR-118 -- PEGylated-naloxol are based on well understood molecules and have enormous therapeutic and commercial potential. We plan to initiate Phase 2 clinical trials for both of these by year-end."

Mr. Robin will host a conference call today for analysts and investors beginning at 1:30 p.m. PST to discuss the company's performance. This conference call will be available via webcast and can be accessed through a link that is posted on the Investor Relations section of the Nektar website, www.nektar.com. The web broadcast of the conference call will be available for replay through May 23, 2007.

To access the conference call via telephone, follow these instructions:

Dial: [phone] (U.S.); [phone] (international).

Passcode: 17659665 (Howard Robin is the host).

[summersonflo]

AP
Out of the Gate: Nektar Therapeutics
Thursday May 10, 9:59 am ET
Nektar Therapeutics Rises on Stronger Exubera Sales and Upgrade

NEW YORK (AP) -- Nektar Therapeutics shares jumped Thursday after the biopharmaceutical company posted a smaller loss and better sales than analysts expected.
After the closing bell Wednesday, Nektar said it reduced its first-quarter loss due to rising sales of its inhaled insulin, Exubera. The San Carlos, Calif., company lost $25.7 million, or 28 cents per share, for the quarter. Revenue nearly tripled, rising to $85 million from $29 million.

Exubera revenue climbed to $59.8 million, up from $1.5 million a year earlier.

Morgan Stanley analyst Jami Rubin upgraded shares to "Equal weight" from "Underweight," saying the company is not spending money as quickly and the stock, down 10.9 percent this year, has not lived up to expectations. He raised his price target to $11 per share, just under Wednesday's closing price, from $9.

Nektar's pipeline includes a powder to fight fungal infections in the lungs, a drug to treat colorectal cancer and other tumors, a constipation relief drug, and an antibiotic for patients with ventilator-related infections.

Nine analysts reporting to Thomson Financial rate the stock at "Buy"-equivalent, with three others rating the stock at "Neutral" or the equivalent.

The stock added 87 cents, or 7.8 percent, to $12.02 in morning trading.

[miristegal]

Antwort auf Beitrag Nr.: 29.253.029 von summersonflo am 10.05.07 16:10:19

Hi summ

danke. es wird zeit , NKTR wieder ins visier zu nehmen.

http://www.exubera.com/content/con_index.jsp?setShowOn=../co…

wer lust hat , kann unter o.g. URL alles über exubera erfahren.

ps. nun bin wieder aktiv dabei.

mfg

[summersonflo]

AP
Nektar Cites Positive Study Results
Monday May 21, 1:00 pm ET
Nektar Therapeutics Cites Positive Study Results for Hospital-Acquired Pneumonia Treatment

SAN CARLOS, Calif. (AP) -- Biotechnology company Nektar Therapeutics said it saw positive results from a midstage study of its NKTR-061 drug candidate to treat hospital-acquired pneumonia.
The results from the Phase IIa clinical trial show the inhaled drug candidate was successful in being delivered to the lungs and was well tolerated in the treatment groups. But, the company said, the impact on antibiotic resistance and the clinical impact still remains to be determined.

"The data in this study are very encouraging because they indicate that the adjunctive use of aerosol antibiotics with systemic therapy might be an effective new approach for treating patients infected by hospital-acquired, gram negative pneumonia, many of whom were infected by resistant gram negative pathogens," said Dr. Michael S. Niederman, chairman of the Department of Medicine at the Winthrop-University Hospital and Professor of Medicine at the State University of New York at Stony Brook.

Increasing gram-negative antibiotic resistance is a growing problem in hospitals, the company said. It is usually acquired by patients in intensive care units who are on ventilators. Between 25 percent and 50 percent of those who acquire it will die.

Shares of Nektar Therapeutics rose 29 cents, or 2.5 percent, to $11.69 in midday trading. The stock has traded between $11.03 and $21.22 over the last 52 weeks.

[miristegal]

Antwort auf Beitrag Nr.: 29.410.397 von summersonflo am 21.05.07 22:09:44

ja, aber dies macht mich krank:

Income Statement Get Income Statement for:




View: Annual Data | Quarterly Data All numbers in thousands
PERIOD ENDING 31-Mar-07 31-Dec-06 30-Sep-06 30-Jun-06
Total Revenue 85,016 69,904 58,632 60,223
Cost of Revenue 56,522 41,142 31,179 36,773

Gross Profit 28,494 28,762 27,453 23,450

Operating Expenses
Research Development 37,492 41,365 34,985 41,630
Selling General and Administrative 16,735 17,441 14,442 26,063
Non Recurring - 9,410 - 17,710
Others 236 708 708 1,259

Total Operating Expenses - 68,924 - 86,662


Operating Income or Loss (25,969) (40,162) (22,682) (63,212)

Income from Continuing Operations
Total Other Income/Expenses Net 5,479 7,056 8,333 5,319
Earnings Before Interest And Taxes (20,490) (33,106) (14,349) (57,893)
Interest Expense 4,933 4,921 5,255 4,938
Income Before Tax (25,423) (38,027) (19,604) (62,831)
Income Tax Expense 250 828 - -
Minority Interest - - - -

Net Income From Continuing Ops (25,673) (38,855) (19,604) (62,831)

Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -


Net Income (25,673) (38,855) (19,604) (62,831)
Preferred Stock And Other Adjustments - - - -

Net Income Applicable To Common Shares ($25,673) ($38,855) ($19,604) ($62,831)


PS.NKTR hat schon so viele medikamente aufm markt gebracht und doch kein ernenneswetren gewinn erzielt. das gefällt mir nicht.

[summersonflo]

Übermorgen kommen die Quartalszahlen, die folgende Meldung klingt schon mal sehr positiv für die Zukunft, nachdem EXUBERA-Erlöse doch deutlich niedriger als erwartet ausfallen kann das vielleicht helfen.

Bayer vereinbart Kooperation mit Nektar Therapeutics

Leverkusen (aktiencheck.de AG) - Die zum Pharmakonzern Bayer AG (ISIN DE0005752000/ WKN 575200) gehörende Tochter Bayer HealthCare hat mit der amerikanischen Nektar Therapeutics Inc. (ISIN US6402681083/ WKN 165417) ein Abkommen zur gemeinsamen Weiterentwicklung und Vermarktung des Wirkstoffs (NKTR-061) Amikacin für die Inhalation als innovative Therapie gegen Lungenentzündung vereinbart.
Laut der am Montag veröffentlichten Pressemitteilung basiert diese innovative Therapie auf einer neuartigen Inhalationstechnologie von Nektar Therapeutics zur Behandlung von Lungenentzündungen, die durch Gram-negative Bakterien verursacht werden. Dabei wird eine spezielle Formulierung von Amikacin - einem Aminoglycosid-Antibiotikum - genutzt. Diese wird über ein Beatmungssystem gezielt an den Ort der Infektion in die tiefen Abschnitte der Lunge transportiert.

Im Rahmen der Vereinbarung erhält Nektar 175 Mio. Dollar in Abhängigkeit von der Erreichung festgelegter Entwicklungs- und Umsatzziele. Darin enthalten ist eine Initialzahlung von 50 Mio. Dollar. Nach dem erfolgreichen Abschluss der klinischen Entwicklung werden Bayer HealthCare und Nektar das Produkt in den USA gemeinsam vermarkten und den Gewinn teilen.

Außerhalb der USA wird Bayer HealthCare das Produkt vermarkten und dafür umsatzabhängig Lizenzgebühren in Höhe von bis zu 30 Prozent an Nektar zahlen, teilte der Konzern weiter mit. Bayer HealthCare ist im Rahmen der Vereinbarung für die weltweite klinische Entwicklung, Arzneimittel-Zulassung und Herstellung des Produkts verantwortlich, hieß es.

Die Aktie von Bayer notiert aktuell mit einem Plus von 0,19 Prozent bei 51,82 Euro, während die Anteilsscheine von Nektar Therapeutics an der Nasdaq aktuell 0,37 Prozent auf 8,11 Dollar abgeben. (06.08.2007/ac/n/d)


Quelle:Finanzen.net 06/08/2007 16:29

[summersonflo]

bizjournals.com
Nektar narrows Q2 loss by 56%
Wednesday August 8, 5:13 pm ET

Nektar Therapeutics said Wednesday it had a second quarter loss of $27.5 million or 30 cents a share, narrowed from a loss of $62.8 million or 70 cents a share in the same period last year.
San Carlos-based Nektar (NASDAQ:NKTR) said the figure included $4.4 million in stock-based compensation and $7.7 million related to a work force reduction charge.

Revenue for the quarter was $65.9 million, up from $60.2 million in the second quarter of 2006.

At the end of the quarter, the company's cash, cash equivalents, and short-term investments were $406.8 million.

Published August 8, 2007 by the Silicon Valley / San Jose Business Journal